172 related articles for article (PubMed ID: 14503938)
1. Alterations of p53 are common in early stage prostate cancer.
Downing SR; Russell PJ; Jackson P
Can J Urol; 2003 Aug; 10(4):1924-33. PubMed ID: 14503938
[TBL] [Abstract][Full Text] [Related]
2. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
3. p53 protein and gene alterations in pathological stage C prostate carcinoma.
Salem CE; Tomasic NA; Elmajian DA; Esrig D; Nichols PW; Taylor CR; Skinner DG; Roy-Burman P; Lieskovsky G; Cote RJ
J Urol; 1997 Aug; 158(2):510-4. PubMed ID: 9224335
[TBL] [Abstract][Full Text] [Related]
4. Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer.
Suzuki H; Komiya A; Aida S; Ito H; Yatani R; Shimazaki J
Prostate; 1996 May; 28(5):318-24. PubMed ID: 8610059
[TBL] [Abstract][Full Text] [Related]
5. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
6. p53 Alteration and chromosomal instability in prostatic high-grade intraepithelial neoplasia and concurrent carcinoma: analysis by immunohistochemistry, interphase in situ hybridization, and sequencing of laser-captured microdissected specimens.
Al-Maghrabi J; Vorobyova L; Chapman W; Jewett M; Zielenska M; Squire JA
Mod Pathol; 2001 Dec; 14(12):1252-62. PubMed ID: 11743048
[TBL] [Abstract][Full Text] [Related]
7. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis.
Kim MJ; Bhatia-Gaur R; Banach-Petrosky WA; Desai N; Wang Y; Hayward SW; Cunha GR; Cardiff RD; Shen MM; Abate-Shen C
Cancer Res; 2002 Jun; 62(11):2999-3004. PubMed ID: 12036903
[TBL] [Abstract][Full Text] [Related]
8. Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers--investigation by temperature gradient gel electrophoresis (TGGE).
Schlechte HH; Schnorr D; Löning T; Rudolph BD; Pohrt UM; Loening SA
J Urol; 1997 Mar; 157(3):1049-53. PubMed ID: 9072541
[TBL] [Abstract][Full Text] [Related]
9. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer.
Zhou Z; Flesken-Nikitin A; Corney DC; Wang W; Goodrich DW; Roy-Burman P; Nikitin AY
Cancer Res; 2006 Aug; 66(16):7889-98. PubMed ID: 16912162
[TBL] [Abstract][Full Text] [Related]
10. An uncertain role for p53 gene alterations in human prostate cancers.
Brooks JD; Bova GS; Ewing CM; Piantadosi S; Carter BS; Robinson JC; Epstein JI; Isaacs WB
Cancer Res; 1996 Aug; 56(16):3814-22. PubMed ID: 8706029
[TBL] [Abstract][Full Text] [Related]
11. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells.
Tepper CG; Gregg JP; Shi XB; Vinall RL; Baron CA; Ryan PE; Desprez PY; Kung HJ; deVere White RW
Prostate; 2005 Dec; 65(4):375-89. PubMed ID: 16037992
[TBL] [Abstract][Full Text] [Related]
12. p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma.
Prendergast NJ; Atkins MR; Schatte EC; Paulson DF; Walther PJ
J Urol; 1996 May; 155(5):1685-92. PubMed ID: 8627854
[TBL] [Abstract][Full Text] [Related]
13. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
Man YG; Gardner WA
Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
[TBL] [Abstract][Full Text] [Related]
14. p53 is mutated in a subset of advanced-stage prostate cancers.
Bookstein R; MacGrogan D; Hilsenbeck SG; Sharkey F; Allred DC
Cancer Res; 1993 Jul; 53(14):3369-73. PubMed ID: 8324747
[TBL] [Abstract][Full Text] [Related]
15. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
[TBL] [Abstract][Full Text] [Related]
16. Integrative analysis of genomic aberrations associated with prostate cancer progression.
Kim JH; Dhanasekaran SM; Mehra R; Tomlins SA; Gu W; Yu J; Kumar-Sinha C; Cao X; Dash A; Wang L; Ghosh D; Shedden K; Montie JE; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
Cancer Res; 2007 Sep; 67(17):8229-39. PubMed ID: 17804737
[TBL] [Abstract][Full Text] [Related]
17. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer.
Hermani A; Hess J; De Servi B; Medunjanin S; Grobholz R; Trojan L; Angel P; Mayer D
Clin Cancer Res; 2005 Jul; 11(14):5146-52. PubMed ID: 16033829
[TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosity of M6P/IGF2R gene is an early event in the development of prostate cancer.
Hu CK; McCall S; Madden J; Huang H; Clough R; Jirtle RL; Anscher MS
Prostate Cancer Prostatic Dis; 2006; 9(1):62-7. PubMed ID: 16304558
[TBL] [Abstract][Full Text] [Related]
19. Expression and role of Foxa proteins in prostate cancer.
Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
[TBL] [Abstract][Full Text] [Related]
20. Allelotyping analysis at chromosome 13q of high-grade prostatic intraepithelial neoplasia and clinically insignificant and significant prostate cancers.
Lu W; Takahashi H; Furusato M; Maekawa S; Nakano M; Meng C; Kikuchi Y; Sudo A; Hano H
Prostate; 2006 Mar; 66(4):405-12. PubMed ID: 16302266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]